Sydney, Feb 6, 2006 (ABN Newswire) - IMUGENE LIMITED Biotech Forum
The Road to Commercialisation; Boardroomradio is pleased to announce that IMUGENE LIMITED (ASX: IMU) has published an audio file. The following presentation "" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: IMUGENE LIMITED (ASX: IMU)
Broadcast Title: No Title
Broadcast Type: Audio stream
View the Audio stream for IMUGENE LIMITED (ASX: IMU) by clicking on the following links.
Display in Windows Media Player
http://www.boardroomradio.com/event/IMU/1277/4482/wmp/221.242.254.150/wsl.wmp?
or:
Display in MP3 Player or Transfer to Portable Podcast Device
http://www.boardroomradio.com/event/IMU/1277/4482/mp3/221.242.254.150/wsl.mp3?
Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.
About Boardroom Media
Boardroom.Media is a new breed of media company that's equal parts publisher, content producer, and streaming media technology business. With a strong footing in capital markets, professional services and asset management, the company has been a leading provider of multimedia communication solutions for corporate Australia for more than a decade.
About Imugene Limited
Imugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.
